Clinical Trial Update: TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 results for a study combining the TORC1/2 inhibitor MLN0128 (sapanisertib) with bevacizumab in adults with recurrent glioblastoma or advanced solid tumo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Fallopian Tube Cancer
• Glioblastoma
• Ovarian Cancer
• Peritoneal Cancer
• Solid Tumor
• Uterine Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• MLN0128 (sapanisertib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Glioblastoma, Endometrial Clear Cell Adenocarcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-10-04